EMA Authorised: Rystiggo (rozanolixizumab) — UCB Pharma

View source ↗

Summary

The European Medicines Agency authorised Rystiggo (rozanolixizumab) for myasthenia gravis, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• RYSTIGGO (rozanolixizumab)

Snippet

Status: Authorised. Therapeutic area: Myasthenia Gravis. MAH: UCB Pharma. Decision date: 16/01/2026. Orphan medicine